Sarcoma / 2019 / Article / Tab 1

Clinical Study

Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)

Table 1

Patients’ baseline characteristics.

CharacteristicAll (N = 25)NF1 MPNST (N = 17)Sporadic MPNST (N = 8)

Median age at diagnosis, years (range)37 (19, 81)28 (19, 63)61 (19, 81)
Female, n (%)15 (60)10 (58.8)5 (62.5)
Asian, n (%)1 (4)1 (5.9)0 (0)
Black or African American, n (%)8 (32)5 (29.4)3 (37.5)
White, n (%)16 (64)11 (64.7)5 (62.5)
Primary tumor location, n (%)
 Extremities10 (40)7 (41.3)3 (37.5)
 Trunk
 Chest wall3 (12)3 (17.6)0 (0)
 Spine2 (8)2 (11.8)0 (0)
 Mediastinal soft tissue1 (4)1 (5.9)0 (0)
 Pelvis2 (8)2 (11.8)0 (0)
 Retroperitoneum1 (4)0 (0)1 (12.5)
 Abdominal wall1 (4)1 (5.9)0 (0)
 Axilla2 (8)1 (5.9)1 (12.5)
 Parotid gland1 (4)0 (0)1 (12.5)
Primary tumor resected, n (%)20 (80)13 (76.5)7 (87.5)
Margins of surgical resection, n (%)
 R0: microscopic negative9 (45)7 (53.8)2 (28.6)
 R1: microscopic positive4 (20)2 (15.4)2 (28.6)
 R2: gross residual disease5 (25)3 (23.1)2 (28.6)
If resected, did the primary tumor locally recur, n (%)N = 20N = 13N = 7
 No5 (25)2 (15.4)3 (42.9)
 Yes15 (75)11 (84.6)4 (57.1)
Metastatic disease at diagnosis, n (%)N = 21N = 13N = 8
 No18 (86)12 (92.3)6 (75)
 Yes3 (14)1 (7.7)2 (25)
Metastatic disease at enrollment, n (%)N = 21N = 13N = 8
 No2 (10)1 (7.7)1 (12.5)
Prior chemotherapy, n (%)
 No2 (8)2 (11.8)0 (0)
 Yes23 (92)15 (88.2)8 (100)
No. of prior treatment regimens
 Median (range)2 (0, 5)2 (0, 5)2 (1, 4)
Patient had prior radiation, N (%)
 No4 (16)3 (17.6)1 (12.5)
 Yes21 (84)14 (82.4)7 (87.5)
No. of prior radiation treatments
 Median (range)1 (0, 3)1 (0, 3)1 (0, 2)
Patient had prior surgeries, N (%)
 No2 (8)1 (5.9)1 (12.5)
 Yes23 (92)16 (94.1)7 (87.5)
No. of prior surgeries
 Median (range)2 (0, 8)2 (0, 8)2 (0, 5)
ECOG at baseline, N (%)
 012 (48)8 (47.1)4 (50)
 111 (44)7 (41.2)4 (50)
 22 (8)2 (11.8)0 (0)

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.